Zobrazeno 1 - 10
of 359
pro vyhledávání: '"Richard G. Vile"'
Autor:
Muriel Metko, Jason Tonne, Alexa Veliz Rios, Jill Thompson, Haley Mudrick, David Masopust, Rosa Maria Diaz, Michael A. Barry, Richard G. Vile
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1191 (2024)
Background: Long-lived, re-activatable immunity to SARS-CoV-2 and its emerging variants will rely on T cells recognizing conserved regions of viral proteins across strains. Heterologous prime–boost regimens can elicit elevated levels of circulating
Externí odkaz:
https://doaj.org/article/d98810f9d5c34f26ac87a699cbde1ffe
Autor:
Katherine E. R. Smith, Kah-Whye Peng, Jose S. Pulido, Adam J. Weisbrod, Carrie A. Strand, Jacob B. Allred, Alysha N. Newsom, Lianwen Zhang, Nandakumar Packiriswamy, Timothy Kottke, Jason M. Tonne, Madelyn Moore, Heather N. Montane, Lisa A. Kottschade, Robert R. McWilliams, Arkadiusz Z. Dudek, Yiyi Yan, Anastasios Dimou, Svetomir N. Markovic, Mark J. Federspiel, Richard G. Vile, Roxana S. Dronca, Matthew S. Block
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMetastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach
Externí odkaz:
https://doaj.org/article/0a92140d4f6e43bc9b4331d5a320712f
Autor:
Luke Kendall, Richard G. Vile
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 42-43 (2023)
Externí odkaz:
https://doaj.org/article/9e75da3a7e0b48c6995707fc6f40b27b
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Glioblastomas (GBMs) are the most common and lethal primary brain malignancy in adults. Oncolytic virus (OV) immunotherapies selectively kill GBM cells in a manner that elicits antitumor immunity. Cellular communication network factor 1 (CCN
Externí odkaz:
https://doaj.org/article/cb6ba4dd71e340d2ac81300b41577f9c
Autor:
Timothy Kottke, Jason Tonne, Laura Evgin, Christopher B. Driscoll, Jacob van Vloten, Victoria A. Jennings, Amanda L. Huff, Brady Zell, Jill M. Thompson, Phonphimon Wongthida, Jose Pulido, Matthew R. Schuelke, Adel Samson, Peter Selby, Elizabeth Ilett, Mark McNiven, Lewis R. Roberts, Mitesh J. Borad, Hardev Pandha, Kevin Harrington, Alan Melcher, Richard G. Vile
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-deriv
Externí odkaz:
https://doaj.org/article/0057781c39ce43a79a6659f6e847a415
Publikováno v:
Pharmaceuticals, Vol 16, Iss 6, p 793 (2023)
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most com
Externí odkaz:
https://doaj.org/article/6e01dc93ed564a09a8e7f5b9538b607b
Autor:
Elizabeth C. Eckert, Rebecca A. Nace, Jason M. Tonne, Laura Evgin, Richard G. Vile, Stephen J. Russell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 16, Iss , Pp 63-74 (2020)
Genetically modified vesicular stomatitis virus (VSV) is an attractive agent for cancer treatment due to rapid intratumoral replication and observed clinical responses. Although VSV selectively kills malignant cells and can boost antitumor immunity,
Externí odkaz:
https://doaj.org/article/5bc51a5e074e4c1d8f38884a5ba05a79
Autor:
Christopher B. Driscoll, Matthew R. Schuelke, Timothy Kottke, Jill M. Thompson, Phonphimon Wongthida, Jason M. Tonne, Amanda L. Huff, Amber Miller, Kevin G. Shim, Amy Molan, Cynthia Wetmore, Peter Selby, Adel Samson, Kevin Harrington, Hardev Pandha, Alan Melcher, Jose S. Pulido, Reuben Harris, Laura Evgin, Richard G. Vile
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
DNA mutations induced by dysregulated APOBEC3 expression are associated with tumour-progression and therapeutic resistance, but also with the generation of neoepitopes. Here, the authors show that APOBEC3 function can be exploited in a vaccine settin
Externí odkaz:
https://doaj.org/article/0b522666697f4ba891fb72be5cba002f
Autor:
Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill M. Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard G. Vile
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 1-13 (2018)
Tumor cells frequently evade applied therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance to infection and lysis is cr
Externí odkaz:
https://doaj.org/article/fd3503b7a0a047429514beaab62c3ec2
Autor:
Zachariah P. Tritz, Katayoun Ayasoufi, Delaney M. Wolf, Carley A. Owens, Courtney S. Malo, Benjamin T. Himes, Cori E. Fain, Emma N. Goddery, Lila T. Yokanovich, Fang Jin, Michael J. Hansen, Ian F. Parney, Chensu Wang, Kelly D. Moynihan, Darrell J. Irvine, K. Dane Wittrup, Rosa M. Diaz Marcano, Richard G. Vile, Aaron J. Johnson
Publikováno v:
Cancer Immunology Research. :OF1-OF14
Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for approximately 225,000 deaths per year. Despite preclinical successes, most interventions have failed to extend patient survival by more than a few months. Treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7540cd53a24c6bdfa3312e808dfa839f
https://doi.org/10.1158/2326-6066.cir-22-0570
https://doi.org/10.1158/2326-6066.cir-22-0570